A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma
Introduction We present a case of novel coronavirus disease‐2019 that underwent combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma. Case presentation A 50‐year‐old man complained of anorexia and weight loss. Contrast‐enhanced computed tomography revealed a solid ma...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-03-01
|
| Series: | IJU Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iju5.12412 |
| _version_ | 1819001202081267712 |
|---|---|
| author | Yu Kijima Tomokazu Shimizu Shinya Kato Eri Sekido Kana Kano Makoto Toguchi Toshihide Horiuchi Hiroshi Toma Shoichi Iida Toshio Takagi |
| author_facet | Yu Kijima Tomokazu Shimizu Shinya Kato Eri Sekido Kana Kano Makoto Toguchi Toshihide Horiuchi Hiroshi Toma Shoichi Iida Toshio Takagi |
| author_sort | Yu Kijima |
| collection | DOAJ |
| description | Introduction We present a case of novel coronavirus disease‐2019 that underwent combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma. Case presentation A 50‐year‐old man complained of anorexia and weight loss. Contrast‐enhanced computed tomography revealed a solid mass of 57 mm in diameter with cysts in the right kidney, along with liver, lung, and multiple bone metastases. Computed tomography‐guided biopsy of the right kidney was performed, and a diagnosis of clear cell renal cell carcinoma was made. Three weeks after nivolumab and ipilimumab administration, the patient contracted coronavirus disease‐2019. Anticoagulation therapy (dalteparin) was administered for 4 days once infection was confirmed, after which dexamethasone was administered for 10 days. The patient survived without experiencing worsened respiratory symptoms. Conclusion We administered nivolumab and ipilimumab combination therapy as treatment for metastatic renal cell carcinoma. No side effects or immune‐related adverse events were observed for a short time. |
| first_indexed | 2024-12-20T22:45:27Z |
| format | Article |
| id | doaj.art-f0720e3698364440960734ccd9661e80 |
| institution | Directory Open Access Journal |
| issn | 2577-171X |
| language | English |
| last_indexed | 2024-12-20T22:45:27Z |
| publishDate | 2022-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | IJU Case Reports |
| spelling | doaj.art-f0720e3698364440960734ccd9661e802022-12-21T19:24:23ZengWileyIJU Case Reports2577-171X2022-03-015212612810.1002/iju5.12412A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinomaYu Kijima0Tomokazu Shimizu1Shinya Kato2Eri Sekido3Kana Kano4Makoto Toguchi5Toshihide Horiuchi6Hiroshi Toma7Shoichi Iida8Toshio Takagi9Department of Urology and Transplant Surgery Toda Chuo General Hospital SaitamaJapanDepartment of Urology and Transplant Surgery Toda Chuo General Hospital SaitamaJapanDepartment of Urology and Transplant Surgery Toda Chuo General Hospital SaitamaJapanDepartment of Urology Tokyo Women’s Medical University Tokyo JapanDepartment of Urology and Transplant Surgery Toda Chuo General Hospital SaitamaJapanDepartment of Urology Tokyo Women’s Medical University Tokyo JapanDepartment of Urology and Transplant Surgery Toda Chuo General Hospital SaitamaJapanDepartment of Urology and Transplant Surgery Toda Chuo General Hospital SaitamaJapanDepartment of Urology and Transplant Surgery Toda Chuo General Hospital SaitamaJapanDepartment of Urology Tokyo Women’s Medical University Tokyo JapanIntroduction We present a case of novel coronavirus disease‐2019 that underwent combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma. Case presentation A 50‐year‐old man complained of anorexia and weight loss. Contrast‐enhanced computed tomography revealed a solid mass of 57 mm in diameter with cysts in the right kidney, along with liver, lung, and multiple bone metastases. Computed tomography‐guided biopsy of the right kidney was performed, and a diagnosis of clear cell renal cell carcinoma was made. Three weeks after nivolumab and ipilimumab administration, the patient contracted coronavirus disease‐2019. Anticoagulation therapy (dalteparin) was administered for 4 days once infection was confirmed, after which dexamethasone was administered for 10 days. The patient survived without experiencing worsened respiratory symptoms. Conclusion We administered nivolumab and ipilimumab combination therapy as treatment for metastatic renal cell carcinoma. No side effects or immune‐related adverse events were observed for a short time.https://doi.org/10.1002/iju5.12412anticoagulantsCOVID‐19drug‐related side effects and adverse reactionsipilimumabnivolumab |
| spellingShingle | Yu Kijima Tomokazu Shimizu Shinya Kato Eri Sekido Kana Kano Makoto Toguchi Toshihide Horiuchi Hiroshi Toma Shoichi Iida Toshio Takagi A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma IJU Case Reports anticoagulants COVID‐19 drug‐related side effects and adverse reactions ipilimumab nivolumab |
| title | A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma |
| title_full | A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma |
| title_fullStr | A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma |
| title_full_unstemmed | A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma |
| title_short | A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma |
| title_sort | case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma |
| topic | anticoagulants COVID‐19 drug‐related side effects and adverse reactions ipilimumab nivolumab |
| url | https://doi.org/10.1002/iju5.12412 |
| work_keys_str_mv | AT yukijima acaseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT tomokazushimizu acaseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT shinyakato acaseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT erisekido acaseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT kanakano acaseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT makototoguchi acaseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT toshihidehoriuchi acaseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT hiroshitoma acaseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT shoichiiida acaseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT toshiotakagi acaseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT yukijima caseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT tomokazushimizu caseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT shinyakato caseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT erisekido caseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT kanakano caseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT makototoguchi caseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT toshihidehoriuchi caseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT hiroshitoma caseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT shoichiiida caseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma AT toshiotakagi caseofnovelcoronavirusdiseaseaftercombinationtherapywithnivolumabandipilimumabformetastaticrenalcellcarcinoma |